Suppr超能文献

使用新型增强型单焦点散光型人工晶状体的白内障手术的真实世界结果。

Real-world outcomes of cataract surgeries using a new type of enhanced monofocal toric intraocular lens.

机构信息

Department of Ophthalmology, Institute of Vision Research, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul, 03722, Republic of Korea.

Department of Ophthalmology, Corneal Dystrophy Research Institute, Severance Hospital, Yonsei University, Seoul, Republic of Korea.

出版信息

Sci Rep. 2024 Nov 12;14(1):27758. doi: 10.1038/s41598-024-65746-2.

Abstract

In this single-center study, 62 eyes of 41 patients with regular astigmatism, who received cataract surgery with TECNIS Eyhance Toric II intraocular lens (IOL) insertion between January 1, 2022, and June 30, 2023, were retrospectively investigated. At 3 months postoperatively, there were significant improvements in the mean logMAR uncorrected distance visual acuity (VA) (from 0.64 ± 0.42 to 0.11 ± 0.13, p < 0.001) and logMAR corrected distance VA (from 0.28 ± 0.30 to 0.03 ± 0.06, p < 0.001). An 81.9% reduction in astigmatism (from 1.66 ± 0.49 D corneal cylinder preoperatively to - 0.30 ± 0.39 D refractive cylinder at 3 months postoperatively, p < 0.001) was observed. In the vector analysis, the average of difference vector was 0.27 ± 0.35 D, and the average correction index was 1.09 ± 0.22, revealing a minimal overcorrection. Mean IOL misalignment at 3 months postoperatively was 0.68 ± 4.17°, and average absolute misalignment was 3.41 ± 2.44°. Defocus curves showed < 0.2 logMAR range between - 0.85 and 1.27 diopters, and distance-corrected near and intermediate VA were 0.38 ± 0.14 and 0.17 ± 0.13, respectively. These results indicate that the new enhanced monofocal toric IOL is a safe and effective treatment for astigmatic eyes with cataract.

摘要

在这项单中心研究中,回顾性分析了 2022 年 1 月 1 日至 2023 年 6 月 30 日期间接受 TECNIS Eyhance Toric II 散光人工晶状体(IOL)植入术的 41 例规则散光患者的 62 只眼。术后 3 个月,平均 logMAR 未矫正距离视力(VA)(从 0.64 ± 0.42 提高到 0.11 ± 0.13,p<0.001)和 logMAR 矫正距离 VA(从 0.28 ± 0.30 提高到 0.03 ± 0.06,p<0.001)均有显著改善。散光从术前 1.66 ± 0.49 D 角膜柱镜减少到术后 3 个月的-0.30 ± 0.39 D 屈光柱镜(p<0.001),减少了 81.9%。在向量分析中,差异向量的平均值为 0.27 ± 0.35 D,平均矫正指数为 1.09 ± 0.22,提示存在最小过矫。术后 3 个月时 IOL 平均偏心度为 0.68 ± 4.17°,平均绝对偏心度为 3.41 ± 2.44°。离焦曲线在-0.85 至 1.27 屈光度之间<0.2 logMAR 范围,远距和中距矫正视力分别为 0.38 ± 0.14 和 0.17 ± 0.13。这些结果表明,新型增强型单焦点散光人工晶状体是治疗白内障伴散光眼的一种安全有效的治疗方法。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2204/11557603/e5a23dd4982a/41598_2024_65746_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验